The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALUMIS INC. | COM | 022307102 | 165,941,439 | 5,896,995 | SH | SOLE | 5,896,995 | 0 | 0 | ||
| CG Oncology, Inc. | COM | 156944100 | 76,666,503 | 1,079,050 | SH | SOLE | 1,079,050 | 0 | 0 | ||
| Disc Medicine, Inc. | COM | 254604101 | 27,359,407 | 374,069 | SH | SOLE | 374,069 | 0 | 0 | ||
| Eikon Therapeutics, Inc. | COM | 282564103 | 17,212,728 | 1,318,983 | SH | SOLE | 1,318,983 | 0 | 0 | ||
| Hims & Hers Health, Inc. | COM CL A | 433000106 | 25,591,695 | 738,151 | SH | SOLE | 738,151 | 0 | 0 | ||
| Lyell Immunopharma, Inc. | COM | 55083R203 | 6,693,223 | 476,386 | SH | SOLE | 476,386 | 0 | 0 | ||
| Odyssey Therapeutics, Inc. | COM | 67613T104 | 13,342,195 | 713,105 | SH | SOLE | 713,105 | 0 | 0 | ||
| Nurix Therapeutics, Inc. | COM | 67080M103 | 6,428,900 | 265,000 | SH | SOLE | 265,000 | 0 | 0 | ||
| Pharvaris N.V. | COM | N69605108 | 22,966,030 | 664,142 | SH | SOLE | 664,142 | 0 | 0 | ||